Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 602

1.

The utility and determination of P crit in fishes.

Ultsch GR, Regan MD.

J Exp Biol. 2019 Nov 13;222(Pt 22). pii: jeb203646. doi: 10.1242/jeb.203646. Review.

PMID:
31722971
2.

Factors associated with depressive symptoms and suicidal ideation and behaviours among sub-Saharan African adolescents aged 10-19 years: Cross-sectional study.

Nyundo A, Manu A, Regan M, Ismail A, Chukwu A, Dessie Y, Njau T, Kaaya SF, Smith Fawzi MC.

Trop Med Int Health. 2019 Nov 7. doi: 10.1111/tmi.13336. [Epub ahead of print] Review.

PMID:
31698526
3.

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.

Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Di Leo A, Coates AS, Goldhirsch A, Gelber RD, Regan MM; SOFT and TEXT Investigators and International Breast Cancer Study Group.

J Clin Oncol. 2019 Oct 16:JCO1801967. doi: 10.1200/JCO.18.01967. [Epub ahead of print]

PMID:
31618131
4.

Current State of and Future Opportunities for Prediction in Microbiome Research: Report from the Mid-Atlantic Microbiome Meet-up in Baltimore on 9 January 2019.

Sakowski E, Uritskiy G, Cooper R, Gomes M, McLaren MR, Meisel JS, Mickol RL, Mintz CD, Mongodin EF, Pop M, Rahman MA, Sanchez A, Timp W, Vela JD, Wolz CM, Zackular JP, Chopyk J, Commichaux S, Davis M, Dluzen D, Ganesan SM, Haruna M, Nasko D, Regan MJ, Sarria S, Shah N, Stacy B, Taylor D, DiRuggiero J, Preheim SP.

mSystems. 2019 Oct 8;4(5). pii: e00392-19. doi: 10.1128/mSystems.00392-19.

5.

Neoadjuvant radiotherapy for rectal cancer management.

Feeney G, Sehgal R, Sheehan M, Hogan A, Regan M, Joyce M, Kerin M.

World J Gastroenterol. 2019 Sep 7;25(33):4850-4869. doi: 10.3748/wjg.v25.i33.4850. Review.

6.

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma.

Regan MM, Werner L, Rao S, Gupte-Singh K, Hodi FS, Kirkwood JM, Kluger HM, Larkin J, Postow MA, Ritchings C, Sznol M, Tarhini AA, Wolchok JD, Atkins MB, McDermott DF.

J Clin Oncol. 2019 Sep 9:JCO1900345. doi: 10.1200/JCO.19.00345. [Epub ahead of print]

PMID:
31498030
7.

Genetic mosaicism in dermatology: Clinical utility of genetic testing of skin lesions.

Doolan BJ, Robinson AJ, Regan M, Ragunathan A, Winship I.

Australas J Dermatol. 2019 Aug 28. doi: 10.1111/ajd.13149. [Epub ahead of print] No abstract available.

PMID:
31463948
8.

Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain.

Jenkins NW, Iriondo C, Shah V, Bahroos E, Ravanfar V, Regan M, Seo Y, Dillon WP, Majumdar S, Talbott JF.

J Vis Exp. 2019 Aug 8;(150). doi: 10.3791/58491.

PMID:
31449234
9.

Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience.

Nakhlis F, Regan MM, Chun YS, Dominici LS, Caterson S, Bellon JR, Warren L, Yeh ED, Jacene HA, King TA, Overmoyer B.

Breast J. 2019 Aug 25. doi: 10.1111/tbj.13509. [Epub ahead of print]

PMID:
31448540
10.

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.

Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann B; Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019.

Ann Oncol. 2019 Oct 1;30(10):1541-1557. doi: 10.1093/annonc/mdz235.

PMID:
31373601
11.

A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses.

Xie W, Halabi S, Tierney JF, Sydes MR, Collette L, Dignam JJ, Buyse M, Sweeney CJ, Regan MM.

JNCI Cancer Spectr. 2019 Feb 6;3(1):pkz002. doi: 10.1093/jncics/pkz002. eCollection 2019 Mar. Review.

12.

Rapid MALDI mass spectrometry imaging for surgical pathology.

Basu SS, Regan MS, Randall EC, Abdelmoula WM, Clark AR, Gimenez-Cassina Lopez B, Cornett DS, Haase A, Santagata S, Agar NYR.

NPJ Precis Oncol. 2019 Jul 4;3:17. doi: 10.1038/s41698-019-0089-y. eCollection 2019.

13.

Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome.

Hackett KL, Davies K, Tarn J, Bragg R, Hargreaves B, Miyamoto S, McMeekin P, Mitchell S, Bowman S, Price EJ, Pease C, Emery P, Andrews J, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Vadivelu S, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Lendrem DW, Ng WF.

RMD Open. 2019 Apr 24;5(1):e000885. doi: 10.1136/rmdopen-2018-000885. eCollection 2019.

14.

Mobile phone conversation distraction: Understanding differences in impact between simulator and naturalistic driving studies.

Wijayaratna KP, Cunningham ML, Regan MA, Jian S, Chand S, Dixit VV.

Accid Anal Prev. 2019 Aug;129:108-118. doi: 10.1016/j.aap.2019.04.017. Epub 2019 May 28. Review.

PMID:
31150917
15.

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.

Denkert C, Budczies J, Regan MM, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua MG, Solbach C, Thürlimann B, Mehta K, Blohmer JU, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner BM, Dietel M, Fasching PA, Viale G.

Breast Cancer Res Treat. 2019 Aug;176(3):557-568. doi: 10.1007/s10549-018-05112-9. Epub 2019 May 7.

PMID:
31065870
16.

Reply to K.-D. Yu et al.

Ruhstaller T, Regan MM.

J Clin Oncol. 2019 Jun 10;37(17):1516-1517. doi: 10.1200/JCO.19.00325. Epub 2019 Apr 29. No abstract available.

PMID:
31034299
17.

Metal Oxide Laser Ionization Mass Spectrometry Imaging (MOLI MSI) Using Cerium(IV) Oxide.

Basu SS, McMinn MH, Giménez-Cassina Lopéz B, Regan MS, Randall EC, Clark AR, Cox CR, Agar NYR.

Anal Chem. 2019 May 21;91(10):6800-6807. doi: 10.1021/acs.analchem.9b00894. Epub 2019 May 8.

PMID:
31025851
18.

Implication of DNA repair genes in Lynch-like syndrome.

Xicola RM, Clark JR, Carroll T, Alvikas J, Marwaha P, Regan MR, Lopez-Giraldez F, Choi J, Emmadi R, Alagiozian-Angelova V, Kupfer SS, Ellis NA, Llor X.

Fam Cancer. 2019 Jul;18(3):331-342. doi: 10.1007/s10689-019-00128-6.

PMID:
30989425
19.

Shifts in metabolic fuel use coincide with maximal rates of ventilation and body surface rewarming in an arousing hibernator.

Regan MD, Chiang E, Martin SL, Porter WP, Assadi-Porter FM, Carey HV.

Am J Physiol Regul Integr Comp Physiol. 2019 Jun 1;316(6):R764-R775. doi: 10.1152/ajpregu.00379.2018. Epub 2019 Apr 10.

PMID:
30969844
20.

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Ribi K, Luo W, Colleoni M, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Di Lauro V, Gomez HL, Ruhstaller T, Abdi E, Biganzoli L, Müller B, Barbeaux A, Graas MP, Rabaglio M, Francis PA, Foukakis T, Pagani O, Graiff C, Vorobiof D, Maibach R, Di Leo A, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J; SOLE Investigators.

Br J Cancer. 2019 May;120(10):959-967. doi: 10.1038/s41416-019-0435-4. Epub 2019 Apr 10.

PMID:
30967649
21.

Prevalence of germline variants in inflammatory breast cancer.

Rana HQ, Sacca R, Drogan C, Gutierrez S, Schlosnagle E, Regan MM, Speare V, LaDuca H, Dolinsky J, Garber JE, Overmoyer BA.

Cancer. 2019 Apr 1. doi: 10.1002/cncr.32062. [Epub ahead of print]

PMID:
30933323
22.

Automatic 3D Nonlinear Registration of Mass Spectrometry Imaging and Magnetic Resonance Imaging Data.

Abdelmoula WM, Regan MS, Lopez BGC, Randall EC, Lawler S, Mladek AC, Nowicki MO, Marin BM, Agar JN, Swanson KR, Kapur T, Sarkaria JN, Wells W, Agar NYR.

Anal Chem. 2019 May 7;91(9):6206-6216. doi: 10.1021/acs.analchem.9b00854. Epub 2019 Apr 22.

PMID:
30932478
23.

Don't throw the fish out with the respirometry water.

Regan MD, Mandic M, Dhillon RS, Lau GY, Farrell AP, Schulte PM, Seibel BA, Speers-Roesch B, Ultsch GR, Richards JG.

J Exp Biol. 2019 Mar 28;222(Pt 6). pii: jeb200253. doi: 10.1242/jeb.200253. No abstract available.

24.

Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.

Regan MM, Fleming GF, Walley B, Francis PA, Pagani O.

J Clin Oncol. 2019 Apr 10;37(11):862-866. doi: 10.1200/JCO.18.02433. Epub 2019 Feb 27. No abstract available.

PMID:
30811287
25.

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.

Kensler KH, Regan MM, Heng YJ, Baker GM, Pyle ME, Schnitt SJ, Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi RM.

Breast Cancer Res. 2019 Feb 22;21(1):30. doi: 10.1186/s13058-019-1118-z.

26.

Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer.

Einstein DJ, Patil D, Chipman J, Regan MM, Davis K, Crociani CM, Wagner AA, Sanda MG, Chang P.

Urology. 2019 May;127:53-60. doi: 10.1016/j.urology.2019.02.004. Epub 2019 Feb 18.

PMID:
30790648
27.

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group.

Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.

PMID:
30765258
28.

Structural elements of a pH-sensitive inhibitor binding site in NMDA receptors.

Regan MC, Zhu Z, Yuan H, Myers SJ, Menaldino DS, Tahirovic YA, Liotta DC, Traynelis SF, Furukawa H.

Nat Commun. 2019 Jan 18;10(1):321. doi: 10.1038/s41467-019-08291-1.

29.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 .

Ann Oncol. 2019 Jul 1;30(7):1181. doi: 10.1093/annonc/mdy537. No abstract available.

30.

Risk of bias assessment of sequence generation: a study of 100 systematic reviews of trials.

Wuytack F, Regan M, Biesty L, Meskell P, Lutomski JE, O'Donnell M, Treweek S, Devane D.

Syst Rev. 2019 Jan 8;8(1):13. doi: 10.1186/s13643-018-0924-1.

31.

Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial.

Dellapasqua S, Gray KP, Munzone E, Rubino D, Gianni L, Johansson H, Viale G, Ribi K, Bernhard J, Kammler R, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Regan MM, Goldhirsch A, Colleoni M; International Breast Cancer Study Group.

J Clin Oncol. 2019 Feb 10;37(5):386-395. doi: 10.1200/JCO.18.00296. Epub 2018 Dec 27.

32.

Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.

Tarhini A, McDermott D, Ambavane A, Gupte-Singh K, Aponte-Ribero V, Ritchings C, Benedict A, Rao S, Regan MM, Atkins M.

Immunotherapy. 2019 Mar;11(4):283-295. doi: 10.2217/imt-2018-0168. Epub 2018 Dec 19.

33.

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.

Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group.

J Clin Oncol. 2019 Jan 10;37(2):105-114. doi: 10.1200/JCO.18.00440. Epub 2018 Nov 26.

PMID:
30475668
34.

Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma.

Randall EC, Emdal KB, Laramy JK, Kim M, Roos A, Calligaris D, Regan MS, Gupta SK, Mladek AC, Carlson BL, Johnson AJ, Lu FK, Xie XS, Joughin BA, Reddy RJ, Peng S, Abdelmoula WM, Jackson PR, Kolluri A, Kellersberger KA, Agar JN, Lauffenburger DA, Swanson KR, Tran NL, Elmquist WF, White FM, Sarkaria JN, Agar NYR.

Nat Commun. 2018 Nov 21;9(1):4904. doi: 10.1038/s41467-018-07334-3.

35.

Blood-brain-barrier organoids for investigating the permeability of CNS therapeutics.

Bergmann S, Lawler SE, Qu Y, Fadzen CM, Wolfe JM, Regan MS, Pentelute BL, Agar NYR, Cho CF.

Nat Protoc. 2018 Dec;13(12):2827-2843. doi: 10.1038/s41596-018-0066-x.

PMID:
30382243
36.

Can variation among hypoxic environments explain why different fish species use different hypoxic survival strategies?

Mandic M, Regan MD.

J Exp Biol. 2018 Oct 31;221(Pt 21). pii: jeb161349. doi: 10.1242/jeb.161349. Review.

37.

Establishing the Genomic Knowledge Matrix for Nursing Science.

Regan M, Engler MB, Coleman B, Daack-Hirsch S, Calzone KA.

J Nurs Scholarsh. 2019 Jan;51(1):50-57. doi: 10.1111/jnu.12427. Epub 2018 Oct 1.

PMID:
30272391
38.

The role of inflammation on the functionality of intracortical microelectrodes.

Gaire J, Lee HC, Hilborn N, Ward R, Regan M, Otto KJ.

J Neural Eng. 2018 Dec;15(6):066027. doi: 10.1088/1741-2552/aae4b6. Epub 2018 Sep 27.

PMID:
30260321
39.

A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.

Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK.

Mol Cancer Ther. 2018 Dec;17(12):2702-2709. doi: 10.1158/1535-7163.MCT-17-1204. Epub 2018 Sep 25.

PMID:
30254185
40.

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, Hershman DL, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA.

J Clin Oncol. 2018 Sep 13:JCO1800242. doi: 10.1200/JCO.18.00242. [Epub ahead of print]

PMID:
30212295
41.

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.

Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A; International Breast Cancer Study Group Trial 23-01.

Lancet Oncol. 2018 Oct;19(10):1385-1393. doi: 10.1016/S1470-2045(18)30380-2. Epub 2018 Sep 5.

PMID:
30196031
42.

Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.

McDermott DF, Shah R, Gupte-Singh K, Sabater J, Luo L, Botteman M, Rao S, Regan MM, Atkins M.

Qual Life Res. 2019 Jan;28(1):109-119. doi: 10.1007/s11136-018-1984-3. Epub 2018 Sep 6.

PMID:
30191365
43.

Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.

Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, Sabater J, Ritchings C, Aponte-Ribero V, Regan MM, Atkins M.

Immunotherapy. 2018 Oct;10(14):1241-1252. doi: 10.2217/imt-2018-0085. Epub 2018 Sep 3.

44.

Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.

Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers H, Floris G, Van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-Hurder A, Regan MM, Viale G, Thürlimann B, Vergote I, Christodoulou E, Van Calster B, Neven P.

Oncologist. 2019 Feb;24(2):165-171. doi: 10.1634/theoncologist.2018-0176. Epub 2018 Aug 31.

PMID:
30171067
45.

Rapid discrimination of pediatric brain tumors by mass spectrometry imaging.

Clark AR, Calligaris D, Regan MS, Pomeranz Krummel D, Agar JN, Kallay L, MacDonald T, Schniederjan M, Santagata S, Pomeroy SL, Agar NYR, Sengupta S.

J Neurooncol. 2018 Nov;140(2):269-279. doi: 10.1007/s11060-018-2978-2. Epub 2018 Aug 20.

46.

Selecting trainee pilots: Predictive validity of the WOMBAT situational awareness pilot selection test.

Caponecchia C, Zheng WY, Regan MA.

Appl Ergon. 2018 Nov;73:100-107. doi: 10.1016/j.apergo.2018.06.004. Epub 2018 Jun 27.

PMID:
30098625
47.

Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis.

Hoye ML, Regan MR, Jensen LA, Lake AM, Reddy LV, Vidensky S, Richard JP, Maragakis NJ, Rothstein JD, Dougherty JD, Miller TM.

Brain. 2018 Sep 1;141(9):2561-2575. doi: 10.1093/brain/awy182.

48.

Enhanced Bacterial Immunity and Mammalian Genome Editing via RNA-Polymerase-Mediated Dislodging of Cas9 from Double-Strand DNA Breaks.

Clarke R, Heler R, MacDougall MS, Yeo NC, Chavez A, Regan M, Hanakahi L, Church GM, Marraffini LA, Merrill BJ.

Mol Cell. 2018 Jul 5;71(1):42-55.e8. doi: 10.1016/j.molcel.2018.06.005.

49.

Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP.

Mihalcik SA, Chipman JJ, Sanda MG, Regan MM, Kaplan ID, Wagner AA, Crociani CM, Chang P; PROST-QA Consortium.

Pract Radiat Oncol. 2018 Nov - Dec;8(6):445-451. doi: 10.1016/j.prro.2018.04.007. Epub 2018 Apr 14. No abstract available.

PMID:
29935957
50.

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.

Luen SJ, Asher R, Lee CK, Savas P, Kammler R, Dell'Orto P, Biasi OM, Demanse D, JeBailey L, Dolan S, Hackl W, Thuerlimann B, Viale G, Colleoni M, Regan MM, Loi S.

JAMA Oncol. 2018 Oct 1;4(10):1335-1343. doi: 10.1001/jamaoncol.2018.1778.

Supplemental Content

Support Center